Recombinant RSV Strains with M2-2 Mutations for Attenuated Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing an effective live attenuated respiratory syncytial virus (RSV) vaccine is challenging due to issues like enhanced disease upon natural infection, inefficient immune control, and genetic instability of RNA viruses, which complicates the attenuation process and immunogenicity.
Innovation Solution
Introducing specific mutations that interfere with the expression of the M2-2 protein in RSV, such as deletions and nucleotide substitutions, to create recombinant strains that are attenuated, self-replicating, and immunogenic, while maintaining genetic stability and avoiding de-attenuation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RSV is attenuated to make a live vaccine, then safety is improved, but immunogenicity is reduced due to reduced replication and antigen synthesis
Solution Approach 1:
The patent applies parameter changes by modifying the M2-2 ORF sequence parameters (nucleotide substitutions, deletions, or insertions) to create attenuation. Specifically, it introduces mutations that reduce M2-2 protein expression while preserving essential viral functions, achieving a balance between safety and immunogenicity through controlled genetic parameter modification
Solution Approach 2:
The patent applies local quality by targeting specific local regions (M2-2 ORF) for modification rather than the entire genome. By focusing attenuation efforts on the M2-2 open reading frame specifically, the invention achieves selective attenuation that preserves overall viral immunogenicity while ensuring safety
2Reliability
If point mutations are introduced to attenuate RSV, then attenuation is achieved, but genetic stability deteriorates due to reversion to wild-type or alternative assignments
Solution Approach 1:
The patent applies segmentation by dividing the M2-2 ORF into multiple target sites for mutation. Instead of relying on a single point mutation that could easily revert, the invention introduces multiple distributed mutations (substitutions, deletions, or insertions) throughout the M2-2 coding sequence, making reversion statistically improbable while maintaining stable attenuation
Solution Approach 2:
The patent applies composite materials by combining multiple types of genetic modifications (nucleotide substitutions, deletions, and/or insertions) within the M2-2 ORF. This composite approach creates a multi-layered attenuation mechanism that enhances genetic stability, as the virus would need to simultaneously revert multiple different mutation types to regain wild-type function
Data Source
AI summary
Provided herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype that contain mutations in the M2-2 open reading frame that interfere with the expression of the M2-2 protein. The M2-2 mutations may be present in combination with mutations at other loci. Using methods described herein, combinations of mutations are provided to achieve desired levels of attenuation. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences of the described viruses, as well as methods for producing and using the viruses.